Editas Medicine, Inc. · NASDAQ:EDIT
Editas Medicine — Shareholder Meeting (May 2021)
17 slides from Editas Medicine's shareholder meeting presentation, May 21, 2021
Slide 1: Governance Engagement Presentation May 2021
Governance Engagement Presentation May 2021
Slide 2: Forward Looking Statements
Forward Looking StatementsThis presentation contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "
Slide 3: A Message From Our CEO
A Message From Our CEO Editas was founded in 2013 with the mission to discover and develop a novel class of genome editing therapeutics. Specifically, our focus is to create therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of disea
Slide 4: Editas is Transforming Medicine
Editas is TransformingMedicine Harnessing the power and potential of gene editing to develop medicines for people living with serious diseases around the world Striving to discover, develop, manufacture, and commercialize transformative, durable genomic medicines
Slide 5: Three Platforms of Medicine Development
Three Platforms of Medicine Development Built on a Powerful Gene Editing Engine and a Talented TeamIn Vivo Global leader in in vivo gene editing medicines, starting with LCA10, moving into other inherited retinal diseases, and eventually into different tissuesCell Therapy Gene edited iPSC NK cells t
Slide 6: Company Highlights
Company HighlightsBest-In-Class In Vivo and Ex Vivo Gene Edited MedicinesFirst ever administration of an in vivo gene editing medicine in humans with EDIT-101 for potentially curing genetic blindnessExpanding in vivo gene editing medicines to address unmet monogenetic diseases worldwideDeveloping ED
Slide 7: Leading in an Interconnected Genome Editing World
Leading in an Interconnected Genome Editing WorldObjectives1. Shaping the broader field of genome editing2. Ensuring patient access to our CRISPR medicinesKey Stakeholders ▪ Patients & caregivers ▪ Regulators ▪ Policy leaders ▪ NGO’s3. Driving corporate image as genomic▪ Patient ▪ Payorsgroupsmedici
Slide 8: Our Commitment to Patients
Our Commitment to PatientsEngage Regularly Seek opportunities to learn from the communities we aim to treat and bring their voice into the decision making and development process.Listen Actively Health and treatment is deeply personal, and there are differences and similarities across all rare disea
Slide 9: Proactive Conversations Across All Forums
Proactive Conversations Across All ForumsEditas works withFor many years, Editas has worked with Mass Eye and Ear on research and clinical programs, including as a site for our LCA10 Natural History Study and for our lead clinical program, the BRILLIANCE study.Editas and Cura worked together on a un
Slide 10: Executive Compensation Philosophy
Executive Compensation PhilosophyOur goal is to implement an executive compensation program that attracts and retains qualified and talented executives, motivates such executives to achieve our business goals and rewards them for short-and long-term performance with a simple and clear compensation s
Slide 11: CEO Compensation Highlights
CEO Compensation HighlightsPerformance based stock options and restricted stock unitsIncentives linked to actions that create sustainable stockholder valueOrganizational MilestonesR&D MilestonesSignificant equity focus strengthens alignment of interests with those of long-term stockholders01 02 03Si
Slide 12: Key Board Highlights
Key Board Highlights60 years3 yearsMeeta Chatterjee, Ph.D.SVP, Global Business Development, Legend BiotechBOARD COMMITTEESAudit, Compensationaverage age of board memberaverage tenure on Editas’ boardAndrew HirschPresident & CEO, C4 TherapeuticsAudit (Chair), CompensationIndex Average = 62.2 years In
Slide 13: Experienced Leadership Team
Experienced Leadership Team28 years Management team average experience2 years Average tenure at Editas MedicineJames Mullen Chairman, President, and Chief Executive OfficerMichelle Robertson Chief Financial Officer Lisa Michaels Chief Medical Officer Gad Berdugo Chief Business OfficerYEARS OF EXPERI
Slide 14: Corporate Governance Highlights
Corporate Governance HighlightsOur governance structure strives to ensure independent oversight of an experienced management team and protection of long-term stockholder value▪ Diverse board ▪ Board oversight of corporate strategy and risk ▪ Stock ownership guidelines for executive officers and dire
Slide 15: Human Capital Management
Human Capital Management Our human capital is integral to Editas’ successOur human capital resources objectives include attracting, retaining, developing and motivating a diverse team of highly skilled employees at all levels.Competitive salary and bonus packages Opportunities for equity ownership,
Slide 16: Representative Differences
Representative Differences Editas regularly reviews representational data and identifies a diverse pool of candidates for all job openings to ensure we remain an inclusive culture that continues to strengthen through diversity.Senior Management All Editas Medicine EmployeesGender DiversityEthnic/Rac
Slide 17: Thank you
Thank youeditasmedicine.com© 2021 Editas Medicine 22